“I need to breathe” — Living with Asthma: Patient Experiences, Old Challenges, New Drugs

"I need to breathe" — Living with Asthma: Patient Experiences, Old Challenges, New Drugs By Kathleen Hoffman, PhD MSPH Earlier this month, the American Lung Association (ALA), Inspire’s partner for the “Living with Asthma” online community, announced that it is looking for patient panelists to participate in a PFDD (Patient-Focused Drug Development) meeting on Pediatric Asthma, to be held virtually on 9/20/2021. “The meeting will consist of an overview of pediatric asthma, an explanation of the Food and Drug Administration’s PFDD meeting process, and two panel sessions,” explained Annette Eyer, the ALA’s National Assistant Vice President [...]

Read More

Aug 2021By |0 Comments

Out of Nowhere: Kidney Cancer

Out of Nowhere: Kidney Cancer By Kathleen Hoffman, PhD MSPH Of the estimated 1.9 million cancers diagnosed each year in the US, around 4 percent are kidney cancers, the most common are renal cell carcinomas (RCC). Around 76,000 new cases will occur in the US in 2021, 48,0000 in men and 27,000 in women. Kidney cancer can occur at any age, but is most likely to be diagnosed between the ages of 55 - 75.1,2,3 Out of the Blue Patients and caregivers describe sudden and unexpected diagnoses of kidney cancer: My husband was just newly diagnosed [...]

Read More

Aug 2021By |0 Comments

Social Media Communities: Blazing a Trail to New Cures

Social Media Communities: Blazing a Trail to New Cures By Kathleen Hoffman, PhD, MSPH The press makes big news of misinformation spread on social media, but two virtual conferences last week -- Patients as Partners USA and Collaboration for Outcomes using Social Media in Oncology (COSMO) -- featured speakers who became patient advocates for their diseases after participating in social media discussion groups. These speakers found and now share valid information in health communities online, and demonstrate, yet again, how participation in social media has expanded scientific knowledge and research. The Patients as Partners USA conference, a [...]

Read More

Apr 2021By |1 Comment

Heart to Heart Talks: Inspire Members and Heart Disease

Heart to Heart Talks: Inspire Members and Heart Disease By Kathleen Hoffman, PhD, MSPH Heart disease is the leading cause of death in the US among men and women, and for most racial and ethnic groups. Responsible for one in four deaths every year, more people die of heart disease than they do of cancer.1 “Heart disease” is a general category, but the most common kind of heart disease in the US, coronary artery disease (CAD), accounts for over half of the fatalities. CAD killed 365,914 people in 2017. Twenty percent of those who die of CAD [...]

Read More

Apr 2021By |2 Comments

The Race to Rescue Livers: Finding Treatments for NASH

The Race to Rescue Livers: Finding Treatments for NASH By Kathleen Hoffman, PhD, MSPH There is a race to develop drugs to treat non-alcoholic steatohepatitis, commonly called NASH. NASH, an aggressive form of liver disease causing inflammation and scarring, already affects 3-12% of the entire US population.1,2 What’s the incentive? There’s currently no approved treatment, and it can be fatal.3 The current standard of care is lifestyle changes. NASH is a more serious form of NAFLD (non-alcoholic fatty liver disease) and can result in cirrhosis.4 Related to obesity and diabetes, but not to alcohol consumption, NAFLD already [...]

Read More

Mar 2021By |0 Comments

Good News about Lung Cancer? Thanks to Bench Science and Pharma

Good News about Lung Cancer? Thanks to Bench Science and Pharma By Kathleen Hoffman, PhD, MSPH Targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors are the good news - making a significant difference in lung cancer mortality, a new study states. Published in The New England Journal of Medicine, the report said, “Mortality from NSCLC decreased even faster than the incidence ...and this decrease was associated with a substantial improvement in survival over time that corresponded to the timing of approval of targeted therapy.” 1Posts and reassurances that people read while visiting the American Lung Association’s Lung [...]

Read More

Nov 2020By |0 Comments

FDA Finalizes First of Four PFDD Industry Guidances

FDA Finalizes First of Four PFDD Industry Guidances By Marina Ness, MA On June 16th, the FDA released the final version of “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input.” This document, referred to as Guidance 1, advises industry on methodologies they can use to collect patient input that will be considered scientifically valid for the drug and device regulatory approval process -- including guidance on using input from social media. It is the first finalized version of the set of four planned guidances for making the patient perspective part of FDA regulatory approval. All of the [...]

Read More

Jun 2020By |0 Comments

Suffering Through the Opioid Crisis: The Language of Chronic Pain

Suffering Through the Opioid Crisis: The Language of Chronic Pain By Claire Harter, MA Market researchers in the pharmaceutical industry need to know their audience - their unmet needs, language, and experiences. Recent research in chronic pain at Inspire reveals the lexicon of chronic pain patients and their experiences with treatment. Pain Management History Documented widespread under-treatment of pain was a major medical health problem prior to the year 2000. The World Health Organization’s Cancer Pain Monograph detailed poor pain management of cancer and post-operative patients in 1986. Multiple publications throughout the 1990s on inadequate assessment [...]

Read More

Feb 2020By |1 Comment

Real World Data to Real World Evidence

Real World Data to Real World Evidence By Kathleen Hoffman, PhD MSPH You’ve started a medication, and you feel “off” in some way. How “off” do you have to feel before you mention it to your doctor or until you or she sends an Adverse Drug Reaction (ADR) report to the FDA through the MedWatch program? On the other hand, how “off” do you have to feel before mentioning it to your peers in an online health community? A study conducted by Inspire and Stanford University found that people mentioned an ADR for a specific drug [...]

Read More

Oct 2019By |0 Comments

The Kidney Cancer Support Community on Inspire

The Kidney Cancer Support Community on Inspire By Kathleen Hoffman, PhD MSPH Of the over 1 million cancers diagnosed each year in the US, around 3 percent are kidney cancers.1 This relatively rare cancer is twice as likely to develop in men as women. Around 73,000 new cases will occur in the US in 2019, about 44,000 men and 29,000 women.2 Kidney Cancer Association Kidney Cancer Support Community on Inspire Started in 2014, the Kidney Cancer Association Kidney Cancer Support Community on Inspire has grown to approximately 2600 members; 64 percent are female, 36 percent male. [...]

Read More

Sep 2019By |0 Comments